Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.55 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6359744 | 0.90 | CYP4F2 (0.51) | PDE3BPDE3AP2RY12CYP4F2CYP4A11 | |
| SCHEMBL4701042 | 0.86 | HDAC3 (0.52) | KDM4EDAOCYP4Z1HTTALOX15 | |
| SCHEMBL22919854 | 0.86 | ALOX15 (0.56) | PDE3BPDE3AP2RY12DAOHTT | |
| SCHEMBL27650579 | 0.85 | PDE3B (0.51) | PDE3BPDE3AP2RY12KDM4EDAO | |
| SCHEMBL3861037 | 0.83 | MAPT (0.52) | PDE3BPDE3AP2RY12CYP4F2CYP4A11 | |
| SCHEMBL5363783 | 0.82 | DAO (0.51) | KDM4EDAOHTTALOX15ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3861033 | 0.82 | MAPT (0.51) | PDE3BPDE3AP2RY12CYP4F2CYP4A11 | |
| SCHEMBL27838094 | 0.81 | ALOX5 (0.57) | PDE3BPDE3AP2RY12KDM4EHTT | |
| SCHEMBL30244780 | 0.80 | DAO (0.52) | DAOHTTALOX15MAPTHDAC3 | |
| SCHEMBL2385413 | 0.80 | CYP4F2 (0.59) | PDE3BPDE3AP2RY12CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015024448-A1 | BENZO PIPERIDINE RING AND BENZO MORPHOLINE RING COMPOUNDS, MANUFACTURING METHOD THEREFOR, AND MEDICAL APPLICATIONS THEREOF | 上海润诺生物科技有限公司 (CN) | 2015-02-26 | — | — | WO | disclosed |
| EP-2081937-B1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1114028-B1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LTD (GB) | 2006-11-29 | — | — | EP | disclosed |
| US-6608084-B1 | Treatment of human or non-human animal patient suffering from, or subject to, condition which can be ameliorated by administration of inhibitor of alpha 4 beta 1 mediated cell adhesion | AVENTIS PHARMA LTD. (GB) | 2003-08-19 | — | — | US | disclosed |
| CN-1323295-A | Azabicyclic compounds for modulating cell adhesion inhibition | AVENTIES PHARMACEUTICAL LTD (GB) | 2001-11-21 | — | — | CN | disclosed |
| EP-1114028-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | Aventis Pharma Limited (GB) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015612-A1 | AZA-BICYCLES WHICH MODULATE THE INHIBITION OF CELL ADHESION | AVENTIS PHARMA LIMITED (GB) | 2000-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | PDE3B 600/4885PDE3A 568/4885P2RY12 1276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.